Background: Neoadjuvant and perioperative chemo-immunotherapy has become the standard of care for eligible patients with resectable stage II–III non-small cell lung cancer (NSCLC) without EGFR or ALK alterations, having shown higher pathological response rates and longer event-free survival (EFS) than chemotherapy alone in phase III trials; however, real-world data remain limited. This study aimed to assess, in clinical practice, the impact of the introduction of neoadjuvant chemo-immunotherapy on pathological response and on the evolution of treatment pathways in stage III disease. Materials and Methods: This single-centre, retrospective study included patients with resectable NSCLC discussed at the Thoracic Oncology multidisciplinary team of the Veneto Institute of Oncology IOV-IRCCS and the University Hospital of Padua between January 2019 and June 2026, grouped according to neoadjuvant treatment: chemotherapy (Group 1, CT), chemo-immunotherapy (Group 2, CT-IO) or investigational regimens within clinical trials (Group 3). The primary endpoint was pathological complete response (pCR) in Groups 1 and 2; secondary endpoints included major pathological response (MPR), EFS, surgical feasibility, tumour-bed composition and safety. Treatment pathways of stage III patients were finally analysed before and after the introduction of neoadjuvant chemo-immunotherapy into clinical practice at our institution (May 2024). Results: In this real-world cohort, CT-IO (n=39) was associated with significantly higher pCR (28.2% vs 8.5%; p=0.0225) and MPR (43.6% vs 17.0%; p=0.0090) rates than CT (n=47). In multivariate analysis, CT-IO (OR 3.74; p=0.028) and partial radiological response (OR 7.62; p=0.006) were independently associated with pCR; with CT-IO, PD-L1 expression ≥50% was also associated with higher response. CT-IO also resulted in more frequent downstaging (83.3% vs 55.8%) and a larger fibro-inflammatory stromal component of the tumour bed (65% vs 32.5%), which was in turn associated with longer EFS (HR 0.52; p=0.007). Surgery was performed in more than 90% of patients in both groups and was never precluded by toxicity, with a similar incidence of grade ≥3 adverse events. With a median follow-up of 14.9 months in Group 2, EFS did not differ significantly between groups (HR 0.56; p=0.132), whereas achieving pCR (HR 0.28; p=0.026) and MPR (HR 0.35; p=0.007) was associated with longer EFS. In Group 3, pCR and MPR rates were 25.0% and 50.0%. Among patients with stage III disease, neoadjuvant/perioperative treatment increased from 29.4% to 46.5% after May 2024, mainly at the expense of upfront surgery, whereas the proportion treated with definitive chemoradiotherapy remained stable (p=0.002). Conclusions: In this real-world study, neoadjuvant chemo-immunotherapy is associated with a significantly higher pathological response than chemotherapy, without compromising surgical feasibility or safety. Radiological response is the main factor associated with response, whereas the role of high PD-L1 expression with chemo-immunotherapy remains to be confirmed. Longer follow-up is needed to clarify its impact on EFS. Despite the limitations of the retrospective, non-randomised design, these findings support the use of chemo-immunotherapy in clinical practice and the central role of early multidisciplinary management in stage III NSCLC, where its introduction was accompanied by a reduced use of upfront surgery.
Introduzione: La chemio-immunoterapia neoadiuvante e perioperatoria è diventata lo standard di cura per pazienti eleggibili con NSCLC in stadio II–III resecabile senza alterazioni di EGFR o ALK, avendo dimostrato negli studi di fase III tassi di risposta patologica più elevati e una sopravvivenza libera da eventi (EFS) più lunga rispetto alla sola chemioterapia; i dati real-world restano tuttavia limitati. Questo studio ha l’obiettivo di valutare, nella pratica clinica, l’impatto dell’introduzione della chemio-immunoterapia neoadiuvante sulla risposta patologica e sull’evoluzione dei percorsi terapeutici nello stadio III. Materiali e Metodi: Questo studio retrospettivo monocentrico ha incluso pazienti con NSCLC resecabile discussi al gruppo multidisciplinare di Oncologia Toracica dell’Istituto Oncologico Veneto IOV-IRCCS e dell’Azienda Ospedale-Università di Padova tra gennaio 2019 e giugno 2026, suddivisi in base al trattamento neoadiuvante: chemioterapia (Gruppo 1, CT), chemio-immunoterapia (Gruppo 2, CT-IO) o regimi sperimentali nell’ambito di studi clinici (Gruppo 3). L’endpoint primario era la risposta patologica completa (pCR) nei Gruppi 1 e 2; gli endpoint secondari includevano risposta patologica maggiore (MPR), EFS, fattibilità chirurgica, composizione del letto tumorale e sicurezza. Sono stati infine analizzati i percorsi terapeutici dei pazienti in stadio III prima e dopo l’introduzione della chemio-immunoterapia neoadiuvante nella pratica clinica del nostro istituto (maggio 2024). Risultati: Nella nostra coorte real-world, la CT-IO (n=39) si è associata a tassi significativamente più elevati di pCR (28,2% vs 8,5%; p=0,0225) e di MPR (43,6% vs 17,0%; p=0,0090) rispetto alla CT (n=47). All’analisi multivariata, la CT-IO (OR 3,74; p=0,028) e la risposta radiologica parziale (OR 7,62; p=0,006) sono risultate associate in modo indipendente alla pCR; con la CT-IO, anche l’espressione di PD-L1 ≥50% si è associata a una maggiore risposta. La CT-IO ha inoltre determinato un downstaging più frequente (83,3% vs 55,8%) e una maggiore componente stromale fibro-infiammatoria del letto tumorale (65% vs 32,5%), a sua volta associata a un’EFS più lunga (HR 0,52; p=0,007). La chirurgia è stata eseguita in oltre il 90% dei pazienti di entrambi i gruppi, senza mai essere preclusa dalla tossicità, con un’incidenza sovrapponibile di eventi avversi di grado ≥3. Con un follow-up mediano di 14,9 mesi nel Gruppo 2, l’EFS non differiva significativamente tra i due gruppi (HR 0,56; p=0,132), mentre il raggiungimento di pCR (HR 0,28; p=0,026) e di MPR (HR 0,35; p=0,007) si è associato a un’EFS più lunga. Nel Gruppo 3, pCR e MPR sono state del 25,0% e del 50,0%. Nei pazienti in stadio III, dopo maggio 2024 il trattamento neoadiuvante/perioperatorio è aumentato dal 29,4% al 46,5%, principalmente a scapito della chirurgia upfront, mentre la quota di chemioradioterapia definitiva è rimasta stabile (p=0,002). Conclusioni: In questo studio real-world, la chemio-immunoterapia neoadiuvante si associa a una risposta patologica significativamente superiore rispetto alla chemioterapia, senza compromettere la fattibilità chirurgica né la sicurezza. La risposta radiologica rappresenta il principale fattore associato alla risposta, mentre il ruolo dell’elevata espressione di PD-L1 con la chemio-immunoterapia resta da confermare. È necessario un follow-up più lungo per chiarirne l’impatto sull’EFS. Pur con i limiti del disegno retrospettivo e non randomizzato, questi risultati supportano l’impiego della chemio-immunoterapia nella pratica clinica e il ruolo centrale di una gestione multidisciplinare precoce nel NSCLC in stadio III, dove la sua introduzione si è accompagnata a un minore ricorso alla chirurgia upfront.
Evolving treatment strategies in early-stage and locally advanced non-small cell lung cancer: the impact of neoadjuvant chemo-immunotherapy in the real world
SANGIORGI, SARA
2024/2025
Abstract
Background: Neoadjuvant and perioperative chemo-immunotherapy has become the standard of care for eligible patients with resectable stage II–III non-small cell lung cancer (NSCLC) without EGFR or ALK alterations, having shown higher pathological response rates and longer event-free survival (EFS) than chemotherapy alone in phase III trials; however, real-world data remain limited. This study aimed to assess, in clinical practice, the impact of the introduction of neoadjuvant chemo-immunotherapy on pathological response and on the evolution of treatment pathways in stage III disease. Materials and Methods: This single-centre, retrospective study included patients with resectable NSCLC discussed at the Thoracic Oncology multidisciplinary team of the Veneto Institute of Oncology IOV-IRCCS and the University Hospital of Padua between January 2019 and June 2026, grouped according to neoadjuvant treatment: chemotherapy (Group 1, CT), chemo-immunotherapy (Group 2, CT-IO) or investigational regimens within clinical trials (Group 3). The primary endpoint was pathological complete response (pCR) in Groups 1 and 2; secondary endpoints included major pathological response (MPR), EFS, surgical feasibility, tumour-bed composition and safety. Treatment pathways of stage III patients were finally analysed before and after the introduction of neoadjuvant chemo-immunotherapy into clinical practice at our institution (May 2024). Results: In this real-world cohort, CT-IO (n=39) was associated with significantly higher pCR (28.2% vs 8.5%; p=0.0225) and MPR (43.6% vs 17.0%; p=0.0090) rates than CT (n=47). In multivariate analysis, CT-IO (OR 3.74; p=0.028) and partial radiological response (OR 7.62; p=0.006) were independently associated with pCR; with CT-IO, PD-L1 expression ≥50% was also associated with higher response. CT-IO also resulted in more frequent downstaging (83.3% vs 55.8%) and a larger fibro-inflammatory stromal component of the tumour bed (65% vs 32.5%), which was in turn associated with longer EFS (HR 0.52; p=0.007). Surgery was performed in more than 90% of patients in both groups and was never precluded by toxicity, with a similar incidence of grade ≥3 adverse events. With a median follow-up of 14.9 months in Group 2, EFS did not differ significantly between groups (HR 0.56; p=0.132), whereas achieving pCR (HR 0.28; p=0.026) and MPR (HR 0.35; p=0.007) was associated with longer EFS. In Group 3, pCR and MPR rates were 25.0% and 50.0%. Among patients with stage III disease, neoadjuvant/perioperative treatment increased from 29.4% to 46.5% after May 2024, mainly at the expense of upfront surgery, whereas the proportion treated with definitive chemoradiotherapy remained stable (p=0.002). Conclusions: In this real-world study, neoadjuvant chemo-immunotherapy is associated with a significantly higher pathological response than chemotherapy, without compromising surgical feasibility or safety. Radiological response is the main factor associated with response, whereas the role of high PD-L1 expression with chemo-immunotherapy remains to be confirmed. Longer follow-up is needed to clarify its impact on EFS. Despite the limitations of the retrospective, non-randomised design, these findings support the use of chemo-immunotherapy in clinical practice and the central role of early multidisciplinary management in stage III NSCLC, where its introduction was accompanied by a reduced use of upfront surgery.| File | Dimensione | Formato | |
|---|---|---|---|
|
Sangiorgi_Sara.pdf
Accesso riservato
Dimensione
2.46 MB
Formato
Adobe PDF
|
2.46 MB | Adobe PDF |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/119679